Manso, L, Hernando, C, Galan, M, Oliveira, M, Cabrera, MA, Bratos, R, Rodriguez, CA, Ruiz-Borrego, M, Blanch, S, Llombart-Cussac, A, Delgado-Mingorance, JI, Alvarez-Busto, I, Gallegos, I, Gonzalez-Cortijo, L, Morales, S, Aguirre, E, Hernando, BA, Ballesteros, A, Ales-Martinez, JE, Reboredo, C, Oltra, A, Gonzalez-Cao, M, Santisteban, M, Malon, D, Echeverria, I, Garcia-Garre, E, Vega, E, Servitja, S, Andres, R, Robles, CE, Lopez, R, Galve, E, Echarri, MJ, Legeren, M, Moreno, F (2020).
Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Breast. Article. 54:286-292.
[doi:10.1016/j.breast.2020.11.005]
Prat, A, Tsai, YH, Pascual, T, Pare, L, Adamo, B, Vidal, M, Braso-Maristany, F, Galvan, P, Brase, JC, Rodrik-Outmezguine, V, Johnston, S, Ciruelos, E, Parker, JS (2020).
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
CLINICAL CANCER RESEARCH. Article. 26(23):6141-6148.
[doi:10.1158/1078-0432.CCR-20-2793]
Ciruelos, E, Villagrasa, P, Pascual, T, Oliveira, M, Pernas, S, Pare, L, Escriva-de-Romani, S, Manso, L, Adamo, B, Martinez, E, Cortes, J, Vazquez, S, Perello, A, Garau, I, Mele, M, Martinez, N, Montano, A, Bermejo, B, Morales, S, Echarri, MJ, Vega, E, Gonzalez-Farre, B, Martinez, D, Galvan, P, Canes, J, Nuciforo, P, Gonzalez, X, Prat, A (2020).
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
CLINICAL CANCER RESEARCH. Article. 26(22):5820-5829.
[doi:10.1158/1078-0432.CCR-20-0844]
Quintela-Fandino, M, Holgado, E, Manso, L, Morales, S, Bermejo, B, Colomer, R, Apala, JV, Blanco, R, Muñoz M, Caleiras, E, Iranzo, V, Martinez, M, Dominguez, O, Hornedo, J, Gonzalez-Cortijo, L, Cortes, J, Gasol Cudos A, Malon, D, Lopez-Alonso, A, Moreno-Ortiz, MC, Mouron, S, Mañes S (2020).
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
BREAST CANCER RESEARCH. Article. 22(1):124-124.
[doi:10.1186/s13058-020-01362-y]
Garrido-Castro, AC, Saura, C, Barroso-Sousa, R, Guo, H, Ciruelos, E, Bermejo, B, Gavila, J, Serra, V, Prat, A, Pare, L, Celiz, P, Villagrasa, P, Li, YS, Savoie, J, Xu, Z, Arteaga, CL, Krop, IE, Solit, DB, Mills, GB, Cantley, LC, Winer, EP, Lin, NU, Rodon, J (2020).
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
BREAST CANCER RESEARCH. Article. 22(1):120-120.
[doi:10.1186/s13058-020-01354-y]
Prat, A, Guarneri, V, Pare, L, Griguolo, G, Pascual, T, Dieci, MV, Chic, N, Gonzalez-Farre, B, Frassoldati, A, Sanfeliu, E, Cejalvo, JM, Munoz, M, Bisagni, G, Braso-Maristany, F, Urso, L, Vidal, M, Brandes, AA, Adamo, B, Musolino, A, Miglietta, F, Conte, B, Oliveira, M, Saura, C, Pernas, S, Alarcon, J, Llombart-Cussac, A, Cortes, J, Manso, L, Lopez, R, Ciruelos, E, Schettini, F, Villagrasa, P, Carey, LA, Perou, CM, Piacentini, F, D'Amico, R, Tagtiapco, E, Parker, JS, Conte, P (2020).
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
LANCET ONCOLOGY. Article. 21(11):1455-1464.
Schettini, F, Sobhani, N, Ianza, A, Triulzi, T, Molteni, A, Lazzari, MC, Strina, C, Milani, M, Corona, SP, Sirico, M, Bernocchi, O, Giudici, F, Cappelletti, MR, Ciruelos, E, Jerusalem, G, Loi, S, Fox, SB, Generali, D (2020).
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
BREAST CANCER RESEARCH AND TREATMENT. Article. 184(2):421-431.
[doi:10.1007/s10549-020-05856-3]
Martin, M, Garcia-Saenz, JA, Manso, L, Llombart, A, Cassinello, A, Atienza, M, Ringeisen, F, Ciruelos, E (2020).
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
FUTURE ONCOLOGY. Review. 16(33):2763-2778.
[doi:10.2217/fon-2020-0604]
Gonzalez-Santiago, S, Saura, C, Ciruelos, E, Alonso, JL, de la Morena, P, Santisteban Eslava M, Gallegos Sancho MI, de Luna, A, Dalmau, E, Servitja, S, Ruiz Borrego M, Chacon, JI (2020).
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
BREAST CANCER RESEARCH AND TREATMENT. Article. 184(2):469-479.
[doi:10.1007/s10549-020-05866-1]
Tjokrowidjaja, A, Lee, CK, Friedlander, M, Gebski, V, Gladieff, L, Ledermann, J, Penson, R, Oza, A, Korach, J, Huzarski, T, Manso, L, Pisano, C, Asher, R, Lord, SJ, Kim, SI, Lee, JY, Colombo, N, Park-Simon, TW, Fujiwara, K, Sonke, G, Vergote, I, Kim, JW, Pujade-Lauraine, E (2020).
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
EUROPEAN JOURNAL OF CANCER. Article. 139:59-67.
[doi:10.1016/j.ejca.2020.08.021]
Ciruelos, E, Jerusalem, G, Martin, M, Tjan-Heijnen VCG, Neven, P, Gavila, J, Montemurro, F, Generali, D, Lang, I, Martinez-Serrano, MJ, Perello, MF, Conte, P (2020).
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(10):1857-1866.
[doi:10.1007/s12094-020-02327-5]
Yamada, A, Kawasaki, M, Miake, Y, Yamada, Y, Blackburn, J, Kawasaki, K, Trakanant, S, Nagai, T, Nihara, J, Kudo, T, Meguro, F, Schmidt-Ullrich, R, Liu, BG, Hu, YL, Page, A, Ramirez, A, Sharpe, PT, Maeda, T, Takagi, R, Ohazama, A (2020).
Overactivation of the NF-kappaB pathway impairs molar enamel formation.
ORAL DISEASES. Article. 26(7):1513-1522.
[doi:10.1111/odi.13384]
Tratwal, J, Bekri, D, Boussema, C, Sarkis, R, Kunz, N, Koliqi, T, Rojas-Sutterlin, S, Schyrr, F, Tavakol, DN, Campos, V, Scheller, EL, Sarro, R, Barcena, C, Bisig, B, Nardi, V, de Leval, L, Burri, O, Naveiras, O (2020).
MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections.
Frontiers in Endocrinology. Article. 11:480-480.
[doi:10.3389/fendo.2020.00480]
Tolosa, P, Sanchez-Torre, A, de Cabo, HB, Sanchez-Bayona, R, Herrera, M, Yarza, R, Lema, L, Manso, L, Ciruelos, E (2020).
Impact of CDK 4/6i withdrawal or dose adjustment on COVID-19 incidence in HR+/HER2-mBC patients during the pandemic.
CLINICAL CANCER RESEARCH. Meeting Abstract. 26(18).
Jerusalem, G, Onesti, CE, Generali, DG, Harbeck, N, Wildiers, H, Curigliano, G, Campone, M, Tjan-Heijnen, V, Martin, M, Cristofanilli, M, Pusztai, L, Bartsch, R, Peeters, M, Berchem, G, Tagliamento, M, Cortes, J, Ruhstaller, T, Ciruelos, EM, Rottey, S, Rugo, HS (2020).
Expected medium and long term impact of the COVID-19 outbreak in oncology
ANNALS OF ONCOLOGY. Meeting Abstract. 31:1205-1206.
[doi:10.1016/j.annonc.2020.08.2317]
Lago, V, Fotopoulou, C, Chiantera, V, Minig, L, Gil-Moreno, A, Cascales-Campos, PA, Jurado, M, Tejerizo, A, Padilla-Iserte, P, Malune, ME, Di Donna, MC, Marina, T, Sanchez-Iglesias, JL, Chiva, L, Olloqui, A, Matute, L, Garcia-Granero, A, Cardenas-Rebollo, JM, Domingo, S (2020).
Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.
GYNECOLOGIC ONCOLOGY. Article. 158(3):603-607.
[doi:10.1016/j.ygyno.2020.05.047]
Diaz-Feijoo, B, Franco, S, Torne, A, Benito, V, Hernandez, A, Lago, V, Rovira, R, Acosta, U, Agusti, N, Gil-Moreno, A, Gil-Ibanez, B, Bebia, V, Tejerizo, A, Perez-Regadera, JF, Lubrano, A, Gonzalez, C, Domingo, S, Ruiz, R, Cobos, P, Luna-Guibourg, R, Gilabert-Estelles, J, Chipiriliu, D, Llueca, A, Piquer, L, Coronado, P, Gracia, M, SEGO Spain-GOG Grp (2020).
Implications of extraperitoneal paraaortic lymphadenectomy to the left renal vein in locally advanced cervical cancer. A Spanish multicenter study
GYNECOLOGIC ONCOLOGY. Article. 158(2):287-293.
[doi:10.1016/j.ygyno.2020.05.004]
Smyth, LM, Tamura, K, Oliveira, M, Ciruelos, EM, Mayer, IA, Sablin, MP, Biganzoli, L, Ambrose, HJ, Ashton, J, Barnicle, A, Cashell, D, Corcoran, C, de Bruin, EC, Foxley, A, Hauser, J, Lindemann JPO, Maudsley, R, McEwen, R, Moschetta, M, Pass, M, Rowlands, V, Schiavon, G, Banerji, U, Scaltriti, M, Taylor, BS, Chandarlapaty, S, Baselga, J, Hyman, DM (2020).
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer.
CLINICAL CANCER RESEARCH. Article. 26(15):3947-3957.
[doi:10.1158/1078-0432.CCR-19-3953]
Rugo, HS, Andre, F, Yamashita, T, Cerda, H, Toledano, I, Stemmer, SM, Jurado, JC, Juric, D, Mayer, I, Ciruelos, EM, Iwata, H, Conte, P, Campone, M, Wilke, C, Mills, D, Lteif, A, Miller, M, Gaudenzi, F, Loibl, S (2020).
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
ANNALS OF ONCOLOGY. Article. 31(8):1001-1010.
[doi:10.1016/j.annonc.2020.05.001]
Ciruelos, EM, Montaño A, Rodriguez, CA, Gonzalez-Flores, E, Lluch, A, Garrigos, L, Quiroga, V, Anton, A, Malon, D, Chacon, JI, Velasco, M, Gonzalez-Cortijo, L, Jolis, L, Echarri, MJ, Muñoz M, Pascual, T, Amigo, Y, Casas, M, Carrasco, E, Casas, A (2020).
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
EUROPEAN JOURNAL OF CANCER CARE. Article. 29(4).
[doi:10.1111/ecc.13253]
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D (2020).
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Oncotarget. Article. 11(23):2172-2181.
[doi:10.18632/oncotarget.27612]
Herrera Juarez M, Tolosa Ortega P, Sanchez de Torre A, Ciruelos Gil E (2020).
Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.
Breast Care. Review. 15(3):208-216.
[doi:10.1159/000508758]
Manso, L, De Velasco, G, Paz-Ares, L (2020).
Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain.
Esmo Open. Letter. 4(Suppl 2).
[doi:10.1136/esmoopen-2020-000828]
Pérez Ramírez S, del Monte-Millan, M, Lopez-Tarruella, S, Martínez Jáñez N, Marquez-Rodas, I, Lobo Samper F, Izarzugaza Perón Y, Rubio Terres C, Rubio Rodríguez D, Garcia-Saenz, JA, Moreno Antón F, Zamora Auñón P, Arroyo Yustos M, Lara Álvarez MÁ, Ciruelos Gil EM, Manso Sánchez L, Echarri González MJ, Guerra Martínez JA, Jara Sánchez C, Bueno Muiño C, García Adrián S, Carrión Galindo JR, Valentín Maganto V, Martin, M (2020).
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.
CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(5):717-724.
[doi:10.1007/s12094-019-02176-x]
Swain, SM, Miles, D, Kim, SB, Im, YH, Im, SA, Semiglazov, V, Ciruelos, E, Schneeweiss, A, Loi, S, Monturus, E, Clark, E, Knott, A, Restuccia, E, Benyunes, MC, Cortes, J, CLEOPATRA Study Grp (2020).
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
LANCET ONCOLOGY. Article. 21(4):519-530.
[doi:10.1016/S1470-2045(19)30863-0]
Tejerizo-Garcia, A, Olloqui, A, Lopez, G, Alvarez-Conejo, C, Caso-Maestro, O, Diez, A (2020).
Step-by-step total pelviperitonectomy with modified posterior pelvic exenteration.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 30(4):558-558.
[doi:10.1136/ijgc-2019-000984]
Gavilá J, De La Haba J, Bermejo B, Rodríguez-Lescure Á, Antón A, Ciruelos E, Brunet J, Muñoz-Couselo E, Santisteban M, Rodríguez Sánchez CA, Santaballa A, Sánchez Rovira P, García Sáenz JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A (2020).
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 22(3):420-428.
[doi:10.1007/s12094-019-02145-4]
Cortes, J, Ciruelos, E, Perez-Garcia, J, Albanell, J, Garcia-Estevez, L, Ruiz-Borrego, M, Espinosa, R, Gallegos, I, Gonzalez, S, Alvarez, I, Llombart, A (2020).
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.
CANCER TREATMENT REVIEWS. Review. 83:101944-101944.
[doi:10.1016/j.ctrv.2019.101944]
Ramis-Zaldivar, JE, Gonzalez-Farre, B, Balague, O, Celis, V, Nadeu, F, Salmeron-Villalobos, J, Andres, M, Martin-Guerrero, I, Garrido-Pontnou, M, Gaafar, A, Suñol M, Barcena, C, Garcia-Bragado, F, Andion, M, Azorin, D, Astigarraga, I, Sagaseta de Ilurdoz M, Sabado, C, Gallego, S, Verdu-Amoros, J, Fernandez-Delgado, R, Perez, V, Tapia, G, Mozos, A, Torrent, M, Solano-Paez, P, Rivas-Delgado, A, Dlouhy, I, Clot, G, Enjuanes, A, Lopez-Guillermo, A, Galera, P, Oberley, MJ, Maguire, A, Ramsower, C, Rimsza, LM, Quintanilla-Martinez, L, Jaffe, ES, Campo, E, Salaverria, I (2020).
IRF4-rearranged Large B-cell lymphoma (LBCL) has a genomic profile distinct to other LBCL in children and young adults.
BLOOD. Article. 135(4):274-286.
[doi:10.1182/blood.2019002699]
Braso-Maristany, F, Griguolo, G, Pascual, T, Pare, L, Nuciforo, P, Llombart-Cussac, A, Bermejo, B, Oliveira, M, Morales, S, Martinez, N, Vidal, M, Adamo, B, Martinez, O, Pernas, S, Lopez, R, Munoz, M, Chic, N, Galvan, P, Garau, I, Manso, L, Alarcon, J, Martinez, E, Gregorio, S, Gomis, RR, Villagrasa, P, Cortes, J, Ciruelos, E, Prat, A (2020).
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
NATURE COMMUNICATIONS. Article. 11(1):385-385.
[doi:10.1038/s41467-019-14111-3]
Page, A, Bravo, A, Suarez-Cabrera, C, Sanchez-Baltasar, R, Oteo, M, Morcillo, MA, Casanova, ML, Segovia, JC, Navarro, M, Ramirez, A (2020).
IKKß overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in mice.
INTERNATIONAL JOURNAL OF ORAL SCIENCE. Article. 12(1):1-1.
[doi:10.1038/s41368-019-0067-9]
Quintela-Fandino, M, Morales, S, Cortes-Salgado, A, Manso, L, Apala, JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion, M, Lopez-Alonso, A, Cortes, J, Guerra, J, Malon, D, Caleiras, E, Mulero, F, Mouron, S (2020).
Randomized phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.
CLINICAL CANCER RESEARCH. Article. 26(1):35-45.
[doi:10.1158/1078-0432.CCR-19-2023]
Cedena, MT, Martin-Clavero, E, Wong, S, Shah, N, Bahri, N, Alonso, R, Barcenas, C, Valeri, A, Salazar Tabares J, Sanchez-Pina, J, Cuellar, C, Martin, T, Wolf, J, Lahuerta, JJ, Martinez-Lopez, J (2020).
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
PLOS ONE. Article. 15(8).
[doi:10.1371/journal.pone.0237155]
Oliver, R, Betoret, RM (2020).
Treatment of primary and recurrent vaginal/vulva cancer
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Editorial Material. 30:18-18.
Jimenez-Heffernan, JA, Munoz-Hernandez, P, Barcena, C (2020).
Kikuchi-Fujimoto Disease-Like Inflammatory Reaction in a Silicone Breast Implant Seroma.
ACTA CYTOLOGICA. Article. 64(4):1-4.
[doi:10.1159/000505253]
Prat, A, Saura, C, Pascual, T, Hernando, C, Muñoz M, Pare, L, González Farré B, Fernandez, PL, Galvan, P, Chic, N, González Farré X, Oliveira, M, Gil-Gil, M, Arumi, M, Ferrer, N, Montaño A, Izarzugaza, Y, Llombart-Cussac, A, Bratos, R, González Santiago S, Martinez, E, Hoyos, S, Rojas, B, Virizuela, JA, Ortega, V, Lopez, R, Celiz, P, Ciruelos, E, Villagrasa, P, Gavila, J (2020).
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
LANCET ONCOLOGY. Article. 21(1):33-43.
[doi:10.1016/S1470-2045(19)30786-7]
Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC, MRC CHORUS study investigators (2018).
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
LANCET ONCOLOGY. Article. 19(12):1680-1687.
[doi:10.1016/S1470-2045(18)30566-7]
Blancas, I, Fontanillas, M, Conde, V, Lao, J, Martinez, E, Sotelo, MJ, Jaen, A, Bayo, JL, Carabantes, F, Illarramendi, JJ, Gordon, MM, Cruz, J, Garcia-Palomo, A, Mendiola, C, Perez-Ruiz, E, Bofill, JS, Baena-Canada, JM, Janez, NM, Esquerdo, G, Ruiz-Borrego, M (2018).
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (vol 20, pg 862, 2018)
CLINICAL & TRANSLATIONAL ONCOLOGY. Correction. 20(12):1631-1632.
[doi:10.1007/s12094-018-1956-7]
Blasco-Benito, S, Seijo-Vila, M, Caro-Villalobos, M, Tundidor, I, Andradas, C, Garcia-Taboada, E, Wade, J, Smith, S, Guzman, M, Perez-Gomez, E, Gordon, M, Sanchez, C (2018).
Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer
BIOCHEMICAL PHARMACOLOGY. Article. 157:285-293.
[doi:10.1016/j.bcp.2018.06.025]
Minig, L, Cabrera, S, Oliver, R, Couso, A, Rubio, MJ, Iacoponi, S, Martin-Salamanca, MB, Carballo-Rastrilla, S, Cadenas-Rebollo, JM, Garcia-Garcia, A, Gil-Ibanez, B, Juan-Fita, MJ, Patrono, MG (2018).
Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study
CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(10):1337-1344.
[doi:10.1007/s12094-018-1865-9]
Jiménez-Heffernan JA, Bárcena C, Muñoz-Hernández P (2018).
Cytological features of breast peri-implant papillary synovial metaplasia
DIAGNOSTIC CYTOPATHOLOGY. Article. 46(9):769-771.
[doi:10.1002/dc.23947]
Vergote, I, von Moos, R, Manso, L, Van Nieuwenhuysen, E, Concin, N, Sessa, C (2018).
Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study
GYNECOLOGIC ONCOLOGY. Article. 150(3):471-477.
[doi:10.1016/j.ygyno.2018.07.018]
Zagorac, I, Fernandez-Gaitero, S, Penning, R, Post, H, Bueno, MJ, Mouron, S, Manso, L, Morente, MM, Alonso, S, Serra, V, Munoz, J, Gomez-Lopez, G, Lopez-Acosta, JF, Jimenez-Renard, V, Gris-Oliver, A, Al-Shahrour, F, Pineiro-Yanez, E, Montoya-Suarez, JL, Apala, JV, Moreno-Torres, A, Colomer, R, Dopazo, A, Heck AJR, Altelaar, M, Quintela-Fandino, M (2018).
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
NATURE COMMUNICATIONS. Article. 9(1):3501-3501.
[doi:10.1038/s41467-018-05742-z]
Pernaut, C, Lopez, F, Ciruelos, E (2018).
Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer
Breast Care. Review. 13(4):244-249.
[doi:10.1159/000491759]
Colomer R, Aranda-Lopez I, Albanell J, Garcia-Caballero T, Ciruelos E, Lopez-Garcia MA, Cortes J, Rojo F, Martin M, Palacios-Calvo J (2018).
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology (vol 20, pg 815, 2018)
CLINICAL & TRANSLATIONAL ONCOLOGY. Correction. 20(8):1093-1095.
[doi:10.1007/s12094-018-1909-1]
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM, SOFT and TEXT Investigators and the International Breast Cancer Study Group (2018).
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE. Article. 379(2):122-137.
[doi:10.1056/NEJMoa1803164]
Blancas, I, Fontanillas, M, Conde, V, Lao, J, Martinez, E, Sotelo, MJ, Jaen, A, Bayo, JL, Carabantes, F, Illarramendi, JJ, Gordon, MM, Cruz, J, Garcia-Palomo, A, Mendiola, C, Perez-Ruiz, E, Bofill, JS, Baena-Canada, JM, Janez, NM, Esquerdo, G, Ruiz-Borrego, M (2018).
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(7):862-869.
[doi:10.1007/s12094-017-1797-9]
Colomer, R, Aranda-Lopez, I, Albanell, J, Garcia-Caballero, T, Ciruelos, E, Lopez-Garcia, MA, Cortes, J, Rojo, F, Martin, M, Palacios-Calvo, J (2018).
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
CLINICAL & TRANSLATIONAL ONCOLOGY. Review. 20(7):815-826.
[doi:10.1007/s12094-017-1800-5]
Pernas, S, Martin, M, Kaufman, PA, Gil-Martin, M, Gomez Pardo P, Lopez-Tarruella, S, Manso, L, Ciruelos, E, Perez-Fidalgo, JA, Hernando, C, Ademuyiwa, FO, Weilbaecher, K, Mayer, I, Pluard, TJ, Martinez Garcia M, Vahdat, L, Perez-Garcia, J, Wach, A, Barker, D, Fung, S, Romagnoli, B, Cortes, J (2018).
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
LANCET ONCOLOGY. Article. 19(6):812-824.
[doi:10.1016/S1470-2045(18)30147-5]
Ciruelos, E, Vidal, M, Martínez de Dueñas E, Martinez-Janez, N, Fernandez, Y, Garcia-Saenz, J, Murillo, L, Carabantes, F, Beliera, A, Fonseca, R, Gavila, J (2018).
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
CLINICAL & TRANSLATIONAL ONCOLOGY. Article. 20(6):753-760.
[doi:10.1007/s12094-017-1784-1]
Carretero-Gonzalez, A, Otero, I, Carril-Ajuria, L, de Velasco, G, Manso, L (2018).
Exosomes: Definition, Role in Tumor Development and Clinical Implications
CANCER MICROENVIRONMENT. Review. 11(1):13-21.
[doi:10.1007/s12307-018-0211-7]
Selle, F, Colombo, N, Korach, J, Mendiola, C, Cardona, A, Ghazi, Y, Oza, AM (2018).
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Article. 28(4):729-737.
[doi:10.1097/IGC.0000000000001221]
Cala, MP, Agullo-Ortuno, MT, Prieto-Garcia, E, Gonzalez-Riano, C, Parrilla-Rubio, L, Barbas, C, Diaz-Garcia, CV, Garcia, A, Pernaut, C, Adeva, J, Riesco, MC, Ruperez, FJ, Lopez-Martin, JA (2018).
Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE. Article. 9(2):348-357.
[doi:10.1002/jcsm.12270]
Prat, A, Brase, JC, Cheng, Y, Nuciforo, P, Pare, L, Pascual, T, Martinez, D, Galvan, P, Vidal, M, Adamo, B, Hortobagyi, G, Baselga, J, Ciruelos, E (2018).
PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 92:117-117.
[doi:10.1016/S0959-8049(18)30574-4]
Kaufman, PA, Pernas, S, Martin, M, Gil-Martin, M, Pardo, PG, Sara, LT, Manso, L, Ciruelos, E, Perez-Fidalgo, JA, Hernando, C, Ademuyiwa, FO, Weilbaecher, K, Mayer, I, Pluard, TJ, Garcia, MM, Vahdat, L, Wach, A, Barker, D, Romagnoli, B, Cortes, J (2018).
Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial
EUROPEAN JOURNAL OF CANCER. Meeting Abstract. 92:117-118.
Oskay-Özcelik G, Alavi S, Richter R, Keller M, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J (2018).
Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.
ANNALS OF ONCOLOGY. Article. 29(4):910-916.
[doi:10.1093/annonc/mdy037]
Brandariz L, Arriba M, García JL, Cano JM, Rueda D, Rubio E, Rodríguez Y, Pérez J, Vivas A, Sánchez C, Tapial S, Pena L, García-Arranz M, García-Olmo D, Urioste M, González-Sarmiento R, Perea J (2018).
Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location.
Oncotarget. Article. 9(20):15302-15311.
[doi:10.18632/oncotarget.24502]
Garrido, ML, Morago, AJ, Rovira, PS, Olarte, PE, Sanchez, CP, Sanchez, LM (2018).
Experience with eribulin in the treatment of elderly women with metastatic breast cancer:case studies
FUTURE ONCOLOGY. Article. 14(7):21-27.
[doi:10.2217/fon-2017-0357]
de Azambuja, E, Saura, C, Nuciforo, P, Frantal, S, Oliveira, M, Zardavas, D, Jallitsch-Halper, A, de la Pena, L, Dubsky, P, Lombard, JM, Vuylsteke, P, Altamirano, CC, Sanchez, C, Ballestrero, A, Colleoni, M, Borges, GS, Ciruelos, E, Bardia, A, Fornier, M, Boer, K, Wilson, TR, Stout, TJ, Hsu, JY, Shi, Y, Piccart, M, Baselga, J, Gnant, M (2018).
Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer
CANCER RESEARCH. Meeting Abstract. 78(4).
Cortes, A, Apala, JV, Malon, D, Guerra, J, Gion-Cortes, M, Manso, L, Hornedo, J, Gonzalez-Cortijo, L, Mouron, S, Quintela-Fandino, M (2018).
CNIO-BR-009 trial: Targeting mitochondrial metabolism with ME-344 in breast cancer upon bevacizumab-induced vascular normalization: A phase 0 randomized clinical trial
CANCER RESEARCH. Meeting Abstract. 78(4).
Gavila, J, Oliveira, M, Pascual, T, Perez, J, Canes, J, Gonzalez, X, Pare, L, Calvo, I, Ciruelos, E, Munoz, M, Virizuela, JA, Ruiz, I, Andres, R, Perello, A, Martinez, J, Morales, S, Marin, M, Martinez, D, Quero, JC, Llombart-Cussac, A, Prat, A (2018).
Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer
CANCER RESEARCH. Meeting Abstract. 78(4).
Nuciforo, P, Holgado, E, Llombart, A, Fasani, R, Pare, L, Pascual, T, Oliveira, M, Martinez, N, Bermejo, B, Vidal, M, Pernas, S, Lopez, R, Munoz, M, Garau, I, Manso, L, Alarcon, J, Martinez, E, Villagrasa, P, Cortes, J, Prat, A (2018).
A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer
CANCER RESEARCH. Meeting Abstract. 78(4).
Gil-Gil, M, Bellet, M, Morales, S, Barnadas, A, Manso, L, Ruiz, IM, Azaro, A, Gil, EC, Martinez, EG, Marinez, N, Mele, M, Soler, T, Villagrasa, P, Pernas, S (2018).
SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety
CANCER RESEARCH. Meeting Abstract. 78(4).
Ciruelos, E, Villagrasa, P, Pare, L, Oliveira, M, de la Pena, L, Pernas, S, Cortes, J, Soberino, J, Adamo, B, Vazquez, S, Martinez, N, Perello, A, Bermejo, B, Martinez, E, Garau, I, Mele, M, Morales, S, Galvan, P, Pascual, T, Nuciforo, P, Gonzalez, X, Prat, A (2018).
PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial
CANCER RESEARCH. Meeting Abstract. 78(4).
Smyth, LM, Oliveira, M, Ciruelos, E, Tamura, K, El-Khoueiry, A, Mita, A, You, B, Renouf, DJ, Sablin, MP, Lluch, A, Mayer, IA, Bando, H, Yamashita, H, Ambrose, H, de Bruin, E, Carr, TH, Corcoran, C, Foxley, A, Lindemann, JPO, Maudsley, R, Pass, M, Rutkowski, A, Schiavon, G, Banerji, U, Scaltriti, M, Taylor, BS, Chandarlapaty, S, Baselga, J, Hyman, DM (2018).
AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer
CANCER RESEARCH. Meeting Abstract. 78(4).
Nuciforo, P, Pascual, T, Cortes, J, Llombart-Cussac, A, Fasani, R, Pare, L, Oliveira, M, Galvan, P, Martinez, N, Bermejo, B, Vidal, M, Pernas, S, Lopez, R, Muñoz M, Garau, I, Manso, L, Alarcon, J, Martinez, E, Rodrik-Outmezguine, V, Brase, JC, Villagrasa, P, Prat, A, Holgado, E (2018).
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
ANNALS OF ONCOLOGY. Article. 29(1):170-177.
[doi:10.1093/annonc/mdx647]
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, Panel Members of the St Gallen International Expert Consensus on the Primary The, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B (2018).
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.
ANNALS OF ONCOLOGY. Letter. 29(1):281-282.
[doi:10.1093/annonc/mdx543]
Di Leo, A, Johnston, S, Lee, KS, Ciruelos, E, Lønning PE, Janni, W, O'Regan, R, Mouret-Reynier, MA, Kalev, D, Egle, D, Csoszi, T, Bordonaro, R, Decker, T, Tjan-Heijnen VCG, Blau, S, Schirone, A, Weber, D, El-Hashimy, M, Dharan, B, Sellami, D, Bachelot, T (2018).
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
LANCET ONCOLOGY. Article. 19(1):87-100.
[doi:10.1016/S1470-2045(17)30688-5]
Leo, AD, Toi, M, Campone, M, Sohn, JH, Shimon, SP, Huober, J, Park, IH, Tredan, O, Chen, SC, Manso, L, Freedman, O, Jaliffe, GG, Forrester, TD, Frenzel, M, Barriga, S, Smith, IC, Bourayou, N, Goetz, MP (2018).
MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
ONCOLOGY RESEARCH AND TREATMENT. Meeting Abstract. 41:5-5.
Manso, L, Sanchez-Munoz, A, Calvo, I, Izarzugaza, Y, Plata, J, Rodriguez, C (2018).
Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer
Breast Care. Review. 13(4):277-283.
[doi:10.1159/000488794]
Redondo, A, Ramos Vazquez M, Manso, L, Gil, MJG, Garau Llinas I, Garcia-Garre, E, Rodriguez, CA, Chacon, JI, Lopez-Vivanco, G (2018).
Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study
ONCOTARGETS AND THERAPY. Article. 11:5845-5852.
[doi:10.2147/OTT.S170303]
Page A, Navarro M, Suárez-Cabrera C, Bravo A, Ramirez A (2017).
Context-Dependent Role of IKKß in Cancer.
Genes. Article. 8(12).
[doi:10.3390/genes8120376]
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017).
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
JOURNAL OF CLINICAL ONCOLOGY. Article. 35(32):3638-3646.
[doi:10.1200/JCO.2017.75.6155]
Díaz-Alonso J, de Salas-Quiroga A, Paraíso-Luna J, García-Rincón D, Garcez PP, Parsons M, Andradas C, Sánchez C, Guillemot F, Guzmán M, Galve-Roperh I (2017).
Loss of Cannabinoid CB1 Receptors Induces Cortical Migration; Malformations and Increases Seizure Susceptibility
CEREBRAL CORTEX. Article. 27(11):5303-5317.
[doi:10.1093/cercor/bhw309]
Oliver-Pérez MLR, Bravo Violeta V, Legorburu Alonso B, Betancor Pérez D, Bebia Conesa V, Jiménez López JS (2017).
Incidence of Anal Dysplasia in a Population of High-Risk Women:; Observations at a Cervical Pathology Unit
JOURNAL OF LOWER GENITAL TRACT DISEASE. Article. 21(4):329-335.
[doi:10.1097/LGT.0000000000000328]
Pont LP, Marcelli S, Robustillo M, Song D, Grandes D, Martin M, Iglesias I, Aso J, Laloumet I, Díaz AJ (2017).
Immediate Breast Reconstruction with Abdominal Free Flap and Adjuvant; Radiotherapy: Evaluation of Quality of Life and Outcomes
PLASTIC AND RECONSTRUCTIVE SURGERY. Article. 140(4):681-690.
[doi:10.1097/PRS.0000000000003664]
Page A, Bravo A, Suarez-Cabrera C, Alameda JP, Casanova ML, Lorz C, Segrelles C, Segovia JC, Paramio JM, Navarro M, Ramirez A (2017).
IKK beta-Mediated Resistance to Skin Cancer Development Is; Ink4a/Arf-Dependent
MOLECULAR CANCER RESEARCH. Article. 15(9):1255-1264.
[doi:10.1158/1541-7786.MCR-17-0157]
Gamez-Pozo, A, Trilla-Fuertes, L, Berges-Soria, J, Selevsek, N, Lopez-Vacas, R, Diaz-Almiron, M, Nanni, P, Arevalillo, JM, Navarro, H, Grossmann, J, Moreno, FG, Rioja, RG, Prado-Vazquez, G, Zapater-Moros, A, Main, P, Feliu, J, del Prado, PM, Zamora, P, Ciruelos, E, Espinosa, E, Vara, JAF (2017).
Functional proteomics outlines the complexity of breast cancer molecular; subtypes
SCIENTIFIC REPORTS. Article. 7(1):10100-10100.
[doi:10.1038/s41598-017-10493-w]
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B (2017).
De-escalating and escalating treatments for early-stage breast cancer:; the St. Gallen International Expert Consensus Conference on the Primary; Therapy of Early Breast Cancer 2017
ANNALS OF ONCOLOGY. Article. 28(8):1700-1712.
[doi:10.1093/annonc/mdx308]
Villalaín-González C, Tejerizo-García Á, Lopez-Garcia P, López-González G, Oliver-Perez MR, Jiménez-López JS (2017).
Vaginal metastasis as the initial presentation of leiomyosarcoma: a case; report
BMC CANCER. Article. 17(1):503-503.
[doi:10.1186/s12885-017-3484-1]
Pascual, T, Apellaniz-Ruiz, M, Pernaut, C, Cueto-Felgueroso, C, Villalba, P, Alvarez, C, Manso, L, Inglada-Perez, L, Robledo, M, Rodriguez-Antona, C, Ciruelos, E (2017).
Polymorphisms associated with everolimus pharmacokinetics, toxicity and; survival in metastatic breast cancer
PLOS ONE. Article. 12(7).
[doi:10.1371/journal.pone.0180192]
Simón E, Tejerizo Á, Muñoz JL, Álvarez C, Marqueta L, Jiménez JS (2017).
Conservative management in ureteric hydronephrosis due to deep; endometriosis: Could the levonorgestrel-intrauterine device be an; option?
JOURNAL OF OBSTETRICS AND GYNAECOLOGY. Article. 37(5):639-644.
[doi:10.1080/01443615.2017.1286467]
Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ciruelos E, Sabidó E, Espinosa E, Fresno Vara JÁ (2017).
Prediction of adjuvant chemotherapy response in triple negative breast; cancer with discovery and targeted proteomics
PLOS ONE. Article. 12(6).
[doi:10.1371/journal.pone.0178296]
Rynne-Vidal A, Au-Yeung CL, Jiménez-Heffernan JA, Pérez-Lozano ML, Cremades-Jimeno L, Bárcena C, Cristóbal-García I, Fernández-Chacón C, Yeung TL, Mok SC, Sandoval P, López-Cabrera M (2017).
Mesothelial-to-mesenchymal transition as a possible therapeutic target; in peritoneal metastasis of ovarian cancer
JOURNAL OF PATHOLOGY. Article. 242(2):140-151.
[doi:10.1002/path.4889]
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS (2017).
A phase II study of combined ridaforolimus and dalotuzumab compared with; exemestane in patients with estrogen receptor-positive breast cancer
BREAST CANCER RESEARCH AND TREATMENT. Article. 163(3):535-544.
[doi:10.1007/s10549-017-4199-3]
Jiménez-Heffernan JA, Freih Fraih A, Álvarez F, Bárcena C, Corbacho C (2017).
Cytologic Features of Pleomorphic Xanthoastrocytoma, WHO Grade II. A; Comparative Study with Glioblastoma
DIAGNOSTIC CYTOPATHOLOGY. Article. 45(4):339-344.
[doi:10.1002/dc.23660]
Alkatout I, Hübner F, Wenners A, Hedderich J, Wiedermann M, Sánchez C, Röcken C, Mathiak M, Maass N, Klapper W (2017).
In situ localization of tumor cells associated with the; epithelial-mesenchymal transition marker Snail and the prognostic impact; of lymphocytes in the tumor microenvironment in invasive ductal breast; cancer
EXPERIMENTAL AND MOLECULAR PATHOLOGY. Article. 102(2):268-275.
[doi:10.1016/j.yexmp.2017.02.013]
Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M (2017).
Limitations in predicting PAM50 intrinsic subtype and risk of relapse; score with Ki67 in estrogen receptor-positive HER2-negative breast; cancer
Oncotarget. Article. 8(13):21930-21937.
[doi:10.18632/oncotarget.15748]
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA (2017).
Critically short telomeres and toxicity of chemotherapy in early breast; cancer
Oncotarget. Article. 8(13):21472-21482.
[doi:10.18632/oncotarget.15592]
Page A, Navarro M, Suarez-Cabrera C, Alameda JP, Casanova ML, Paramio JM, Bravo A, Ramirez A (2017).
Protective role of p53 in skin cancer: Carcinogenesis studies in mice; lacking epidermal p53 (vol 7, pg 20902, 2016)
Oncotarget. Correction. 8(13):22304-22304.
[doi:10.18632/oncotarget.16592]
Suárez-Cabrera C, Quintana RM, Bravo A, Casanova ML, Page A, Alameda JP, Paramio JM, Maroto A, Salamanca J, Dupuy AJ, Ramírez A, Navarro M (2017).
A Transposon-based Analysis Reveals RASA1 Is Involved in Triple-Negative Breast Cancer
CANCER RESEARCH. Article. 77(6):1357-1368.
[doi:10.1158/0008-5472.CAN-16-1586]
Di Leo, A., Lee, K. Seok, Ciruelos, E., Lonning, P., Janni, W., O'Regan, R., Reynier, M-A Mouret, Kalev, D., Egle, D., Csoszi, T., Bordonaro, R., Decker, T., Tjan-Heijnen, V. C., Blau, S., Schirone, A., Weber, D., El-Hashimy, M., Dharan, B., Sellami, D., Bachelot, T. (2017).
BELLE-3: A phase III study of buparlisib plus fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-S4-07]
Pascual, T., Gamez-Pozo, A., Camara-Jurado, M., Manso, L. M., Perez-Campos, A., Trilla, L., Fresno-Vara, J. A., Ciruelos, E. M. (2017).
Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-07-09]
Martin, M., Kahan, Z., Carrasco, E., Bartlett, C. H., Casas, M., Gil-Gil, M., Munoz, M., Ciruelos, E. M., Ruiz-Borrego, M., Margeli, M., Anton, A., Bermejo, B., Morales, S., Gal-Yam, E., Koehler, M., Garcia-Saenz, J. A., de la Haba, J., Chacon, I., Zielinski, C. (2017).
Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. ``The PEARL study'' (GEICAM/2013-02)
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT2-01-06]
Manso Sanchez, L., Moreno Anton, F., Izarzugaza Peron, Y., Delgado Mingorance, I., Borrega Garcia, P., Echarri Gonzalez, M. J., Martinez Janez, N., Lopez Gonzalez, A., Olier Garate, C., Ballesteros Garcia, A., Chacon Lopez-Muniz, I., Ciruelos Gil, E. M., Garcia Saenz, J. A., Paz-Ares Rodriguez, L. (2017).
High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P6-07-21]
Gavila, J., Perez-Garcia, J., Calvo, I., Ciruelos, E., Munoz, M., Virizuela, J. A., Ruiz, I., Andres, R., Morales, S., Perello, A., Sanchez, P., Garcia-Saenz, J. A., Quero Guillen, J. C., Gonzalez-Santiago, S., Garau Llinas, I., Gonzalez-Martin, A., Sanchez de Ibarguen, B. Cantos, Zaragoza, K., de la Pena, L., Llombart-Cussac, A., Oliveira, M. (2017).
Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+breast cancer - Final results of the SOLTI OPTI-HER HEART study
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-05]
Bachelot, T., Puglisi, F., Ciruelos, E., Peretz-Yablonski, T., Schneeweiss, A., Easton, V., Lindegger, N., Restuccia, E., Miles, D. (2017).
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-04]
Colomer, R., Ciruelos, E., De la Haba, J., Martin, M., De Salas-Cansado, M., Munoz-Molina, B., Albanell, J. (2017).
Estimating costs of relapsing HER2+breast cancer in Spain
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P3-12-05]
Ciruelos, E. M., Montano, A., Rodriguez, C. A., Gonzalez-Flores, E., Lluch, A., Garrigos, L., Quiroga, V., Anton, A., Malon, D., Chacon, J. I., Velasco, M., Gonzalez-Cortijo, L., Jolis, L., Pascual, T., Amigo, Y., Casas, M., Camara, M. C., Carrasco, E., Casas, A. (2017).
Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P4-21-16]
Andre, F., Kaufman, B., Juric, D., Ciruelos, E. M., Iwata, H., Mayer, I. A., Rugo, H. S., Conte, P., Liobl, S., Rubovszky, G., Inoue, K., Tesch, H., Lu, Y-S, Ryvo, L., Longin, A-S, Mills, D., Wilke, C., Germa, C., Campone, M. (2017).
SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT2-01-04]
Adamo, B., Vidal, M., Gomez Pardo, P., Zaragoza, K., Ciruelos, E., Virizuela, J. A., Blanch Tormo, S., Perez-Fidalgo, J. A., Murillo, L., Lopez-Gonzalez, A., Amillano Parraga, K., Martinez Janez, N., Gonzalez Farre, X., Prat, A. (2017).
VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in Eluminal/HER2-negative early breast cancer: A window of opportunity trial
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-OT1-01-04]
Abanell, J., Ciruelos, E., De la Haba, J., Martin, M., Munoz-Molina, B., De Salas-Cansado, M., Colomer, R. (2017).
Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+breast cancer in Spain
CANCER RESEARCH. Meeting Abstract. 77(4).
[doi:10.1158/1538-7445.SABCS16-P3-12-02]
Deurloo, R, Colombo, N, Mendiola, C, Selle, F, Korach, J, Oestergaard, MZ, Bylesjo, M, Urban, HJ, Ghazi, Y, Oza, A (2017).
Gene mutational analyses in 154 ovarian cancer (OC) samples from the; ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC
ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Di Leo, A, Toi, M, Campone, M, Sohn, J, Paluch-Shimon, S, Huober, J, Park, IH, Tredan, O, Chen, SC, Manso, L, Freedman, O, Jaliffe, GG, Forrester, T, Frenzel, M, Barriga, S, Smith, IC, Bourayou, N, Goetz, MP (2017).
MONARCH 3: Abemaciclib as initial therapy for patients with; HR+/HER2-advanced breast cancer
ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Lopez-Martin, JA, Cala, M, Prieto-Garcia, E, Riano, CG, Diaz-Garcia, CV, Garcia, A, Marques, VP, Pascualena, FR, Garcia-Ruiz, I, Pernaut, C, Otero, I, Rubio, LP, Riesco, MC, Alfonso, JA, Barbas, C, Agullo-Ortuno, MT (2017).
Metabolomics in cancer cachexia
ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Barcena, C, Rojas, K, Lema, L, Sanchez, LM, Rios, J, Garcia-Martin, R, Maroto, A, Rodriguez-Peralto, JL, Gil, EMC, Mendiola, DC, Paz-Ares, L (2017).
Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade; serous ovarian cancer: Variation with neoadjuvant chemotherapy and; prognostic value
ANNALS OF ONCOLOGY. Meeting Abstract. 28.
Adamo, B, Fidalgo, JAP, Ciruelos, E, Vidal, M, Blanch, S, Lopez, A, Pardo, PG, Murillo, L, Amillano, K, Janez, NM, Gonzalez, X, Canes, J, Prat, A (2017).
VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral; metronomic vinorelbine to endocrine therapy in luminal/HER2-negative; early breast cancer: A window of opportunity trial
ANNALS OF ONCOLOGY. Meeting Abstract. 28.
